Module 9 Quiz

A  All cell types

B  Human cells

C  Bacterial cells

D  Fungal cells

A  Number of genes

B  Presence of double-stranded DNA

C  Number of chromosomes

D  Structure of chromosomes

A  adding nucleotides to primed sites of the DNA strands.

B  unwinding and separating the double-stranded DNA.

C  binding of the primers to the single-stranded DNA.

D  making a cDNA from an mRNA strand.

A  Deletion of a deoxyribonucleotide

B  Addition of a ribonucleotide

C  Addition of a dideoxynucleotide

D  Addition of a deoxyribonucleotide

A  Oligoligated control

B  Blank control

C  dTTP control

D  Positive control

A  Polymerase

B  Lysozyme

C  Transcriptase

D  Restriction enzyme

A  sequence of nucleotides that codes for a protein.

B  sequence of three nucleotides.

C  phosphate group, a ribose sugar, and nitrogen.

D  polymeric molecule composed of nucleic acids.

A  Phosphate group

B  Hydroxyl group

C  Hydrogen

D  Methyl group

A  hormones.

B  nucleotides.

C  histones.

D  lysosomes.

A  20%

B  40%

C  60%

D  30%

A  metabolic pattern.

B  pattern constellation.

C  toxidrome.

D  toxin effect.

A  immunoassay.

B  spectrophotometry.

C  flame ionization gas chromatography (GC).

D  HPLC.

A  The hepatic necrosis is caused by depletion of a substance in the liver and eventual accumulation of the oxidized metabolite.

B  The coma produced is caused by an immediate decrease in sensitivity to CO2 concentration through depression of respiratory centers in the brain.

C  The myocardial infarction is caused by the effect on respiratory centers in the brain and eventual lack of stimulation of the heart.

D  The metabolic acidosis produced is caused by increased formation of formic acid by the liver during metabolism.

A  [HCO3-]  − [Na+ + Cl−].

B  [Na+] − [Cl− +  [HCO3-]

C  [Na+] + [Cl− +  [HCO3-]

D  [Cl−] + [Na+ +  [HCO3-]

A  a more sensitive and specific immunoassay procedure.

B  a spot test.

C  GC-MS.

D  electrophoresis.

A  Immediately before a dose of the drug is given.

B  Immediately after a dose of the drug is given.

C  There is no specific time that is the best for blood collection.

D  At 8 AM, when liver metabolism is highest.

A  To check patient compliance

B  To monitor significant drug-drug interactions

C  To determine drug concentrations in a pathophysiological state

D  To monitor drugs with a broad therapeutic range

A  Increased drug metabolism caused by central nervous system disease

B  Decreased renal elimination leading to increased free drug concentration

C  Using a single drug as opposed to multiple drugs for treatment

D  Using a different route of administration than is typically used for that drug

A  Lipoprotein

B  α1-Glycoprotein

C  Albumin, Lipoprotein, and α1-Glycoprotein

D  Albumin

A  dosing curve.

B  subtherapeutic range.

C  half-life.

D  volume of distribution.